RadComp Newsletter - January 2023

RadComp™

PATIENT POWERED

A study at the heart of breast cancer treatment



Why YOU are important to the RadComp Clinical Trial

Large clinical trials like the RadComp Study seek to learn how medical treatments affect the national community. Where ever you are from, your participation adds to the depth and integrity of the final study findings.

Read More



What is a "Pragmatic Clinical Trial"

What does it mean to be part of a "pragmatic" clinical trial? Pragmatic Clinical Trials are conducted in normal clinical practice settings by qualified physicians. Often results indicated in explanatory clinical trials research perform differently when studied in pragmatic clinical trials.

Read More

Are Your Quality of Life Questionnaires Up to Date?

RadComp seeks to learn about participant quality-of-life through treatment. To do this, we ask participants to complete questionnaires at



certain time-points. [Click to learn more about RadComp questionnaires: (in English)](#) [(in Spanish)](#)

Complete Questionnaire
(*After logging in, if you do not see a questionnaire to complete then you do not have one due at this time. Thank you!).

Advocacy Partner Events & Resources



Pictured above, Sharon Rivera-Sanchez speakings at the House of Representatives regarding the Comprehensive Cancer Survivorship Act in December 2022.

National Coalition for Cancer Survivorship Featured Advocate

RadComp Stakeholder Advisory Committee member Sharon Rivera-Sanchez has been a busy person. In December, she spoke at the House of Representatives on behalf of the Comprehensive Cancer Survivorship Act, and in January, she was featured in NCCS Advocacy Spotlight.

Read More

LIVING BEYOND BREAST CANCER®



Living Beyond Breast Cancer

You have options:
Breast reconstruction decisions

Dates and Times:
Wednesday, February 1, 2023
7:00 pm to 8:15 pm ET
Location: Virtual
Cost: Free*

*There is no fee to attend this program, but you must register in advance to access the live sessions.

Register Now

Publication

Congratulations to Gary Freedman of Penn Medicine on his recent publication:




Proton beam therapy causing pericarditis – a rare case of radiation induced cardiotoxicity

doi: 10.1186/s40959-022-00135-0

Email Gary Freedman

Study Participant Enrollment



As of December 31, 2022, **1155** participants have joined the RadComp Trial, **4** in December.

We are **90%** of the way to complete enrollment of 1,278 participants! Together, we are powering the future of breast cancer treatment.

December Physician Enrollers

More About RadComp



Visit our website

Study Locations

Clinicaltrials.gov

This newsletter was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-1403-12804). The views, statements, and opinions presented are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee.

The RadComp Study Coordinating Center, University of Pennsylvania, Penn Medicine | 3400 Civic Center Blvd. | Philadelphia, PA 19104 US

Unsubscribe | Update Profile | Constant Contact Data Notice



Try email marketing for free today!